Search

Your search keyword '"Zemla T"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Zemla T" Remove constraint Author: "Zemla T"
39 results on '"Zemla T"'

Search Results

1. On the high-pressure superconducting phase in platinum hydride

2. LB 02.1 Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial

3. Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas (PDAC)

5. LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

6. 1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

10. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

14. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

15. Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.

16. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.

17. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.

18. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).

19. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection.

20. Association between physical activity and the time course of cancer recurrence in stage III colon cancer.

21. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).

22. Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).

23. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.

24. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga.

25. Reply to F. Nichetti et al.

26. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.

27. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

28. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

29. Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303.

30. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial.

31. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.

32. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

33. Reply to S. Sorscher.

34. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

35. Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).

36. Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups.

37. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

38. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).

39. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis.

Catalog

Books, media, physical & digital resources